Medicinal cannabis in palliative medicine: lessons learnt from randomised controlled trials.

Gurgenci, T; Hardy, J; Olson, R; Huggett, G; Foster, K; Good, P

Medicinal cannabis in palliative medicine: lessons learnt from randomised controlled trials.

Gurgenci, T Hardy, J Olson, R Huggett, G Foster, K Good, P

Permalink

Publisher:: BMJ PUBLISHING GROUP
Publication Type:: Journal Article
Citation:: BMJ Support Palliat Care, 2023, 13, (2), pp. 238-240
Issue Date:: 2023-06

Closed Access

	Filename	Description	Size
	238.full.pdf		257.85 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Gurgenci, T
dc.contributor.author	Hardy, J
dc.contributor.author	Olson, R
dc.contributor.author	Huggett, G
dc.contributor.author	Foster, K
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.date.accessioned	2023-09-11T04:19:25Z
dc.date.available	2022-10-28
dc.date.available	2023-09-11T04:19:25Z
dc.date.issued	2023-06
dc.identifier.citation	BMJ Support Palliat Care, 2023, 13, (2), pp. 238-240
dc.identifier.issn	2045-435X
dc.identifier.issn	2045-4368
dc.identifier.uri	http://hdl.handle.net/10453/172032
dc.description.abstract	OBJECTIVES: To detail important lessons learnt while conducting several large, medicinal cannabis (MC) randomised clinical trials in a palliative cancer population. METHODS: Investigators involved in these trials had several meetings to agree on the major lessons learnt and how the various challenges could be mitigated in the future. RESULTS: The lessons were sorted into separate categories: patient confidentiality, family dynamics, driving, cost, unfounded beliefs, accessing specific MC products, trial funding, telehealth and COVID-19, and miscellaneous issues. CONCLUSION: Using MC as the intervention arm in such trials entails some unique regulatory, logistical and other challenges. This short report presents key lessons learnt in conducting these randomised controlled trials in a palliative care population for the benefit of future investigators planning similar trials in a similar patient population.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	BMJ PUBLISHING GROUP
dc.relation.ispartof	BMJ Support Palliat Care
dc.relation.isbasedon	10.1136/spcare-2022-004035
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1110 Nursing, 1117 Public Health and Health Services
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4205 Nursing
dc.subject.mesh	Humans
dc.subject.mesh	COVID-19
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Palliative Medicine
dc.subject.mesh	Palliative Care
dc.subject.mesh	Neoplasms
dc.subject.mesh	Randomized Controlled Trials as Topic
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Palliative Care
dc.subject.mesh	Randomized Controlled Trials as Topic
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Palliative Medicine
dc.subject.mesh	COVID-19
dc.subject.mesh	Humans
dc.subject.mesh	COVID-19
dc.subject.mesh	Medical Marijuana
dc.subject.mesh	Palliative Medicine
dc.subject.mesh	Palliative Care
dc.subject.mesh	Neoplasms
dc.subject.mesh	Randomized Controlled Trials as Topic
dc.title	Medicinal cannabis in palliative medicine: lessons learnt from randomised controlled trials.
dc.type	Journal Article
utslib.citation.volume	13
utslib.location.activity	England
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	closed_access	*
dc.date.updated	2023-09-11T04:19:24Z
pubs.issue	2
pubs.publication-status	Published
pubs.volume	13
utslib.citation.issue	2

Abstract:

OBJECTIVES: To detail important lessons learnt while conducting several large, medicinal cannabis (MC) randomised clinical trials in a palliative cancer population. METHODS: Investigators involved in these trials had several meetings to agree on the major lessons learnt and how the various challenges could be mitigated in the future. RESULTS: The lessons were sorted into separate categories: patient confidentiality, family dynamics, driving, cost, unfounded beliefs, accessing specific MC products, trial funding, telehealth and COVID-19, and miscellaneous issues. CONCLUSION: Using MC as the intervention arm in such trials entails some unique regulatory, logistical and other challenges. This short report presents key lessons learnt in conducting these randomised controlled trials in a palliative care population for the benefit of future investigators planning similar trials in a similar patient population.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/172032